arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cytosorbents Corp

CTSO
$5.18 ▼ -0.17 (-3.18%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
80 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cytosorbents Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $325.3M
Dividend Yield —
Revenue Growth 0.2% ↘
Op. Margin -27.4% ↗
ROIC -12.6% →
FCF / Share $-0.01 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -22.96
info Valuation on last close. End-of-day price, Sep 23, 2026.

80-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.63M
— +0.2% —
Net Income Profit after all expenses
$-4.42M
↑ +13.9% —
Operating Margin Operating profit as % of sales
-27.4%
↑ +20.3% 6th
FCF / Share Free cash flow per share
$-0.01
↑ +61.5% —
Long-Term Debt Long-term obligations
$17.24M
↑ +1.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
8
Returns ↓
6
Financial Health →
21
Cash Quality ↑
80

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 29 years · 80 quarters